Eli Lilly became the first U.S. healthcare company valued above $1 trillion.
Eli Lilly crossed the $1 trillion market-capitalization threshold in 2024 as investors responded to strong demand and expectations for its diabetes and obesity medicines. The company’s market value reflected confidence in products such as Mounjaro and Zepbound, which use tirzepatide and became major commercial successes.
Market capitalization is not the same as annual sales or the value of a company’s pharmaceutical pipeline. It represents the stock market’s current valuation of all outstanding shares and can change substantially with clinical, regulatory, and commercial news.
Eli Lilly is sometimes confused with Novo Nordisk because both companies became major participants in the diabetes and obesity-drug market. They are separate companies headquartered in the United States and Denmark, respectively.